Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zolgensma (onasemnogene abeparvovec)
Pharma
Novartis peels back Zolgensma IT data in older SMA patients
Two data sets indicate the potential for intrathecal Zolgensma to be a meaningful treatment option for older patients with SMA, Novartis argues.
Angus Liu
Mar 19, 2025 9:00am
Roche picks up FDA nod for easier Evrysdi dosing format in SMA
Feb 12, 2025 2:30pm
Novartis readies intrathecal Zolgensma for older SMA patients
Jan 2, 2025 12:30pm
BMS takes over Novartis' gene therapy plant in Illinois
Apr 26, 2023 10:25am
Performance slump takes toll on Novartis' CEO's 2022 payout
Mar 8, 2023 9:33am
Biogen's new CEO looks to ads to boost new drugs
Feb 16, 2023 9:10am
.jpg?VersionId=q4GwTDTSG74TowmgwTM7k8SOdrX6o.bX)
